Clinical Trial Update: An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells [Phase 2]

View source ↗

Summary

Phase 2 exploratory safety trial comparing G-CSF alone versus G-CSF plus plerixafor in multiple myeloma patients who may be poor mobilizers, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• G-CSF (granulocyte colony-stimulating factor)
• Plerixafor (Plerixafor)

Snippet

Sponsor: Sanofi | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED